Banking or Bankrupting: Strategies for Sustaining the Economic Future of Public Cord Blood Banks

Jeremy Magalon, Martin Maiers, Joanne Kurtzberg, Cristina Navarrete, Pablo Rubinstein, Colin Brown, Catherine Schramm, Jérome Larghero, Sandrine Katsahian, Christian Chabannon, Christophe Picard, Alexander Platz, Alexander Schmidt, Gregory Katz, Jeremy Magalon, Martin Maiers, Joanne Kurtzberg, Cristina Navarrete, Pablo Rubinstein, Colin Brown, Catherine Schramm, Jérome Larghero, Sandrine Katsahian, Christian Chabannon, Christophe Picard, Alexander Platz, Alexander Schmidt, Gregory Katz

Abstract

Background: Cord blood is an important source of stem cells. However, nearly 90% of public cord blood banks have declared that they are struggling to maintain their financial sustainability and avoid bankruptcy. The objective of this study is to evaluate how characteristics of cord blood units influence their utilization, then use this information to model the economic viability and therapeutic value of different banking strategies.

Methods: Retrospective analysis of cord blood data registered between January 1st, 2009 and December 31st, 2011 in Bone Marrow Donor Worldwide. Data were collected from four public banks in France, Germany and the USA. Samples were eligible for inclusion in the analysis if data on cord blood and maternal HLA typing and biological characteristics after processing were available (total nucleated and CD34+ cell counts). 9,396 banked cord blood units were analyzed, of which 5,815 were Caucasian in origin. A multivariate logistic regression model assessed the influence of three parameters on the CBU utilization rate: ethnic background, total nucleated and CD34+ cell counts. From this model, we elaborated a Utilization Score reflecting the probability of transplantation for each cord blood unit. We stratified three Utilization Score thresholds representing four different banking strategies, from the least selective (scenario A) to the most selective (scenario D). We measured the cost-effectiveness ratio for each strategy by comparing performance in terms of number of transplanted cord blood units and level of financial deficit.

Results: When comparing inputs and outputs over three years, Scenario A represented the most extreme case as it delivered the highest therapeutic value for patients (284 CBUs transplanted) along with the highest financial deficit (USD 5.89 million). We found that scenario C resulted in 219 CBUs transplanted with a limited deficit (USD 0.98 million) that charities and public health could realistically finance over the long term. We also found that using a pre-freezing level of 18 x 10(8) TNC would be the most cost-effective strategy for a public bank.

Conclusion: Our study shows that a swift transition from strategy A to C can play a vital role in preventing public cord blood banks worldwide from collapsing.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. ROC curve derived from multivariate…
Fig 1. ROC curve derived from multivariate analysis.
Fig 2. Banking strategies according to utilization…
Fig 2. Banking strategies according to utilization rate and utilization score (US).
Fig 3. Therapeutic and economic value based…
Fig 3. Therapeutic and economic value based on banking strategies.
Four recruitment strategies were considered: (A) Banks implement an average selectivity rate of 33%, which reflects the percentage of banked units vs. collected units. The level is increased by applying the Utilization Score up to a total selectivity of 20% (B), then 6% (C) and 2% (D). For each scenario, therapeutic value (left scale) is indicated by the number of transplanted CBUs and confronted to the economic value in USD (right scale). The table presents the operating results for each scenario.

References

    1. Ballen KK, E Gluckman, HE Broxmeyer. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013; 122(4):491–498.
    1. Stavropoulos-Giokas C, Chatzistamatiou T, Michalopoulos E, Papassavas A. The Future of Cord Blood Banks, in Cord Blood Stem Cells Medicine. Stavropoulos-Giokas C, Charron D, Navarette C, eds. Elsevier; 2015: p 291–303.
    1. WMDA annual report cord blood Bank/Registries. 2013. Available on request at mail@wmda.info.
    1. Foeken L, Orsini D. International Development and Import/Export–WMDA, in Cord Blood Stem Cells Medicine. Stavropoulos-Giokas C, Charron D, Navarette C, eds. Elsevier; 2015: p 279.
    1. El-Cheikh J, Crocchiolo R, Furst S, Bramanti S, Sarina B, Granata A, et al. Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies. Cancer. 2015. February 3. [Epub ahead of print]
    1. Katz G. Industrial Economics of Cord Blood Banks, in Cord Blood Stem Cells Medicine. Stavropoulos-Giokas C, Charron D, Navarette C, eds. Elsevier; 2015: pp 325–345.
    1. Page KM, Zhang L, Mendizabal A, Wease S, Carter S, Shoulars K, et al. The Cord Blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation. Transfusion. 2012;52(2):272–283.
    1. Allan D, Petraszko T, Elmoazzen H, Smith S. A review of factors influencing the banking of collected umbilical cord blood units [published online February 25,2013]. Stem cells international. 10.1155/2013/463031
    1. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369(9577):1947–1954.
    1. Lee YH, Kim JY, Mun YC, Koo HH. A proposal for improvement in the utilization rate of banked cord blood. Blood research. 2013;48(1):5–7.
    1. Lauber S, Latta M, Kluter H, Muller-Steinhardt M. The Mannheim Cord Blood Bank: Experiences and Perspectives for the Future. Transfusion medicine and hemotherapy. 2010;37(2):90–97.
    1. Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. The lancet oncology. 2011;12(13):1214–1221.
    1. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BS, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611–1618.
    1. Barker JN, Byam CE, Kernan NA, Lee SS, Hawke RM, Doshi KA, et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2010;16(11):1541–1548.
    1. Schmidt AH, Sauter J, Pingel J, Ehninger G. Toward an optimal global stem cell donor recruitment strategy [published online January 30,2014]. PLOS ONE. 2014;9(1):e86605
    1. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. The New England journal of medicine. 2014;371(4):339–348.
    1. Maiers M, Gragert L, Klitz W. High-resolution HLA alleles and haplotypes in the United States population. Human immunology. 2007;68(9):779–788.
    1. Magalon J, Billard-Daufresne LM, Gilbertas C, Hermanche E, Simon S, Lemarie C, et al. Assessing the HLA diversity of cord blood units collected from a birth clinic caring for pregnant women in an ethnically diverse metropolitan area. Transfusion. 2014;54(4):1046–1054.
    1. Bordoni C, Magalon J, Gilbertas C, Gamerre M, Le Coz P, Berthomieu M, et al. Cord blood collection and banking from a population with highly diverse geographic origins increase HLA diversity in the registry and do not lower the proportion of validated cord blood units: experience of the Marseille cord blood bank [published online January 26,2015]. Bone marrow transplantation. 10.1038/bmt.2014.314
    1. Sanchez-Mazas A, Fernandez-Vina M, Middleton D, Hollenbach JA, Buhler S, Di D, et al. Immunogenetics as a tool in anthropological studies. Immunology. 2011;133(2):143–164.
    1. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clinical chemistry. 2008;54(1):17–23.
    1. Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation. 2007;115(5):654–657.
    1. Bart T, Boo M, Balabanova S, Fischer Y, Nicoloso G, Foeken L, et al. Impact of selection of cord blood units from the United States and swiss registries on the cost of banking operations. Transfusion medicine and hemotherapy. 2013;40(1):14–20.
    1. Querol S, Mufti GJ, Marsh SG, Pagliuca A,Little AM, Shawn BE, et al. Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be? Haematologica. 2009; 94(4):536–41.
    1. Page KM, Mendizabal A, Betz-Stablein B, Wease S, Shoulars K, Gentry T, et al. Optimizing donor selection for public cord blood banking: influence of maternal, infant, and collection characteristics on cord blood unit quality. Transfusion. 2014;54(2):340–52.
    1. Katz G, Mills A. Cord blood banking in France: reorganising the national network. Transfusion and apheresis science. 2010;42(3):307–316.
    1. Katz Benichou G. Umbilical Cord Blood Banking: Economic & Therapeutic Challenges. International Journal of Healthcare Technology and Management. 2007;5(8):464–477.
    1. Horwitz ME, Chao NJ, Rizzieri DA, Long GD, Sullivan KM, Gasparetto C, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. The Journal of clinical investigation. 2014;124(7):3121–3128.
    1. Olson AL, Shpall EJ.Cord Blood Cells for Clinical Use: Expansion and Manipulation, Cord Blood Stem Cells Medicine. Stavropoulos-Giokas C, Charron D, Navarette C, eds. Elsevier; 2015: pp 141–149.
    1. Rao M, Ahrlund-Richter L, Kaufman D. Concise review: cord blood banking, transplantaiton and induced pluripotent stem cell: success and opportunities. Stem Cells 2012; 30:55–60. 10.1002/stem.770
    1. Sun JM, Kurtzberg J. Emerging Uses of Cord Blood in Regenerative Medicine–Neurological Applications, Cord Blood Stem Cells Medicine. Stavropoulos-Giokas C, Charron D, Navarette C, eds. Elsevier; 2015: pp 167–177.
    1. Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, et al.Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord bloodtransplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011; 12(13):1214–21.
    1. Van der Zanden HG, Van Rood JJ, Oudshoorn M, Bakker JN, Melis A, Brand A, et al. Non inherited maternal antigens identify acceptable HLA mismatches: benefit to patients and cost-effectiveness for cord blood banks. Biol Blood Marrow Transplant. 2014; 20(11):1791–5.

Source: PubMed

3
Subskrybuj